Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 14, Issue 28, Pages 4434-4439Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.14.4434
Keywords
chemoprevention; colorectal cancer; cyclooxygenase-2; epidermal growth factor receptor; inflammatory bowel disease; mesalazine; Wnt/beta-catenin
Categories
Ask authors/readers for more resources
Patients with ulcerative colitis (UC) and Crohn's disease (CD) are at increased risk for developing colorectal cancer (CRC), and this is believed to be a result of chronic inflammation. Although conclusive evidence is still missing, both epidemiological and experimental observations suggest that certain drugs used to treat inflammation, such as mesalazine, can reduce the incidence of colitis-associated CRC. Therefore, in recent years, several studies have been conducted to dissect the mechanisms by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular mechanisms that underlie the antineoplastic action of mesalazine. (C) 2008 The WJG Press. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available